Becaplermin
- Atc Codes:A01AD08#D03AX06
- CAS Codes:165101-51-9
- PHARMGKB ID:165101-51-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Regranex; Cyprus: Regranex; Czech Republic: Regranex; Estonia: Regranex; France: Regranex; Germany: Regranex; Ireland: Regranex; Latvia: Regranex; Lithuania: Regranex; Malta: Regranex; Netherlands: Regranex; Poland: Regranex; Portugal: Regranex; Romania: Regranex; Slovakia: Regranex; Spain: Regranex; Sweden: Regranex; UK: Regranex.
North America
Canada: Regranex; USA: Regranex.
Latin America
Mexico: Regranex.
Drug combinations
Chemistry
Becaplermin: Mw: approx. 30 kDa (SDS-PAGE determined). Recombinant human platelet-derived growth factor B. A recombinant protein produced by genetically-engineered Saccharomyces cerevisiae cells, which is similar in aa composition and biological activity to the endogenous human PDGF-BB homodimer. CAS-165101-51-9 (1995).
Pharmacologic Category
Skin and Mucous Membrane Agents, Miscellaneous; Platelet-derived Growth Factor. (ATC-Code: A01AD08; D03AX06).
Mechanism of action
B-isoform homodimer of human platelet-derived growth factor (rPDGF-BB) which enhances formation of new granulation tissue, induces fibroblast proliferation and differentiation to promote wound healing, and promotes angiogenesis.
Therapeutic use
Adjunctive treatment of diabetic neuropathic ulcers on the lower limbs which extend into subcutaneous tissue and have adequate blood supply.
Pregnancy and lactiation implications
Use in pregnancy only if clearly needed. Use cautiously during lactation.
Unlabeled use
Contraindications
Hypersensitivity to becaplermin or any component of the formulation. Known neoplasm(s) at the site(s) of application.
Warnings and precautions
An increase in mortality secondary to systemic malignancies observed. Use with caution in known malignancy. Use only topically. Do not use in wounds that close by primary intention. Caution in wounds related to vascular insufficiency and burns.